A vaccine delivery system promotes strong immune responses against SARS‐CoV‐2 variants
Z Lei, L Zhu, P Pan, Z Ruan, Y Gu, X Xia… - Journal of Medical …, 2023 - Wiley Online Library
Abstract Global coronavirus disease 2019 (COVID‐19) pandemics highlight the need of
developing vaccines with universal and durable protection against emerging SARS‐CoV‐2 …
developing vaccines with universal and durable protection against emerging SARS‐CoV‐2 …
[HTML][HTML] Current advances in the development of SARS-CoV-2 vaccines
A Awadasseid, Y Wu, Y Tanaka… - International journal of …, 2021 - ncbi.nlm.nih.gov
Abstract Coronavirus disease 2019 (COVID-19) caused by severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2) is now a global pandemic that has wreaked havoc …
syndrome coronavirus 2 (SARS-CoV-2) is now a global pandemic that has wreaked havoc …
Immunogenicity and protective efficacy of a recombinant protein subunit vaccine and an inactivated vaccine against SARS-CoV-2 variants in non-human primates
Q He, Q Mao, X Peng, Z He, S Lu, J Zhang… - Signal transduction and …, 2022 - nature.com
Emerging SARS-CoV-2 variants and the gradually decreasing neutralizing antibodies over
time post vaccination have led to an increase in incidents of breakthrough infection across …
time post vaccination have led to an increase in incidents of breakthrough infection across …
Non-glycosylated SARS-CoV-2 RBD elicited a robust neutralizing antibody response in mice
Q Ke, P Sun, T Wang, T Mi, H Xu, J Wu, B Liu - Journal of Immunological …, 2022 - Elsevier
The glycosylated receptor-binding domain (glycoRBD) of SARS-CoV-2 can induce
protective neutralizing antibodies to function as a vaccine. However, it is unclear whether …
protective neutralizing antibodies to function as a vaccine. However, it is unclear whether …
Receptor‐binding domain‐based SARS‐CoV‐2 vaccine adjuvanted with cyclic di‐adenosine monophosphate enhances humoral and cellular immunity in mice
MJ Germanó, C Giai, DE Cargnelutti… - Journal of Medical …, 2023 - Wiley Online Library
Novel adjuvants are highly desired to improve immune responses of SARS‐CoV‐2
vaccines. This work reports the potential of the stimulator of interferon genes (STING) …
vaccines. This work reports the potential of the stimulator of interferon genes (STING) …
Immunodominant SARS‐CoV‐2‐specific CD4+ and CD8+ T‐cell responses elicited by inactivated vaccines in healthy adults
J Ning, Q Wang, Y Chen, T He, F Zhang… - Journal of Medical …, 2023 - Wiley Online Library
Safety profiles and humoral responses to inactivated severe acute respiratory syndrome
coronavirus 2 (SARS‐CoV‐2) vaccines have been previously assessed, but cellular immune …
coronavirus 2 (SARS‐CoV‐2) vaccines have been previously assessed, but cellular immune …
Potential SARS-CoV-2 vaccines: Concept, progress, and challenges
SA Hosseini, F Zahedipour, H Mirzaei… - International …, 2021 - Elsevier
Since September 2020, the world has had more than 28 million cases of coronavirus
disease 2019 (COVID-19). Many countries are facing a second wave of the COVID-19 …
disease 2019 (COVID-19). Many countries are facing a second wave of the COVID-19 …
Preclinical study of a DNA vaccine targeting SARS-CoV-2
H Hayashi, J Sun, Y Yanagida, T Otera… - Current research in …, 2022 - Elsevier
To fight against the worldwide COVID-19 pandemic, the development of an effective and
safe vaccine against SARS-CoV-2 is required. As potential pandemic vaccines, DNA/RNA …
safe vaccine against SARS-CoV-2 is required. As potential pandemic vaccines, DNA/RNA …
Recombinant COVID-19 vaccine based on recombinant RBD/Nucleoprotein and saponin adjuvant induces long-lasting neutralizing antibodies and cellular immunity
A Ghaemi, P Roshani Asl, H Zargaran… - Frontiers in …, 2022 - frontiersin.org
SARS-CoV-2 has caused a global pandemic, infecting millions of people. An effective
preventive vaccine against this virus is urgently needed. Here, we designed and developed …
preventive vaccine against this virus is urgently needed. Here, we designed and developed …
A hepatitis B virus core antigen‐based virus‐like particle vaccine expressing SARS‐CoV‐2 B and T cell epitopes induces epitope‐specific humoral and cell‐mediated …
AM Hassebroek, H Sooryanarain… - Journal of medical …, 2023 - Wiley Online Library
The hepatitis B virus core antigen (HBcAg) tolerates insertion of foreign epitopes and
maintains its ability to self‐assemble into virus‐like particles (VLPs). We constructed a∆ …
maintains its ability to self‐assemble into virus‐like particles (VLPs). We constructed a∆ …
相关搜索
- sars cov 2 vaccines
- sars cov cell responses
- sars cov immunity in mice
- sars cov adenosine monophosphate
- sars cov protective efficacy
- sars cov healthy adults
- saponin adjuvant cellular immunity
- neutralizing antibodies cellular immunity
- cell responses inactivated vaccines
- inactivated vaccine protective efficacy
- healthy adults inactivated vaccines
- sars cov inactivated vaccines
- sars cov dna vaccine
- sars cov antibody response